| 摘要 |
Use of a compound of the formula Het-A-B-Ar and the salts thereof with physiologically tolerated acids, in the manufacture of a medicament for treating disorders that respond to dopamine D3 receptor antagonists, wherein: A is a straight or branched alkylene group which contains at least one group which is selected from among O, S, NR4, CONR4, NR4 CO, COO, and OCO; B is a radical of formulae (I); Ar is a phenyl, pyridyl, pyrimidyl or triazinyl, where Ar may have one to four substituents selected from the group consisting of OR4, alkyl, alkenyl, alkynyl, halogen, CN, CO2R4, NO2, SO2R4, SO3R4, NR4R5, SO2NR4R5, SR4, CF3, CHF2, a 5- or a 6-membered carbocyclic, aromatic or non-aromatic ring and a 5- or a 6-membered heterocyclic, aromatic or non-aromatic ring having 1 to 3 hetero atoms which are selected from O, S and N, where the carbocyclic or the heterocyclic ring is unsubstituted or substituted by alkyl, halogen, O-alkyl, OH, NO2 or CF3, and where Ar may also be fused to a 5- or 6-membered carbocyclic, aromatic ring or to a 5- or 6-membered heterocyclic, aromatic or non-aromatic ring having 1 to 3 heteroatoms which are selected from O, S and N, where the carbocyclic or the heterocyclic ring is unsubstituted or substituted by -alkyl, halogen, O-alkyl, OH, NO2 or CF3; Het is a group of formulae (II); R1, R2 and R3 are, independently of one another, H, halogen, OR5, NR4R5, SR4, CF3, CN or alkyl which is unsubstituted or substituted by OH, O-alkyl or halogen; R4 is H or alkyl unsubstituted or substituted by OH, O-alkyl or halogen; R5 is the meaning indicated for R4 or is COR4 or CO2R4.
|
